[go: up one dir, main page]

PE20100467A1 - Compuesto mono-l-malato (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y composiciones que lo contienen - Google Patents

Compuesto mono-l-malato (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y composiciones que lo contienen

Info

Publication number
PE20100467A1
PE20100467A1 PE2009001282A PE2009001282A PE20100467A1 PE 20100467 A1 PE20100467 A1 PE 20100467A1 PE 2009001282 A PE2009001282 A PE 2009001282A PE 2009001282 A PE2009001282 A PE 2009001282A PE 20100467 A1 PE20100467 A1 PE 20100467A1
Authority
PE
Peru
Prior art keywords
iloxi
tetrahydropyran
pyrrolidin
malate
mono
Prior art date
Application number
PE2009001282A
Other languages
English (en)
Inventor
Srinivisa Rao Akireddy
Timothy J Cuthbertson
Gregory J Gatto
Craig Harrison Miller
Pieter Albert Otten
Scott R Breining
Gary Maurice Dull
John Genus
Joseph Pike Mitchener Jr
Daniel Yohannes
Balwinder Singh Bhatti
Nikolai Fedorov
Philip S Hammond
Julio A Munoz
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PE20100467A1 publication Critical patent/PE20100467A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE AL COMPUESTO (R)-3-((E)-2-(PIRROLIDIN-3-IL)VINIL)-5-(TETRAHIDROPIRAN-4-ILOXI)PIRIDINA Y A SUS SALES MONO-L-MALATO, HEMIGALACTARATO, OXALATO Y DI-P-TOLUOIL-D-TARTRATO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA DE DICHO COMPUESTO O DE UNA DE SUS SALES. DICHO COMPUESTO Y SUS SALES SON MODULADORES DE LOS RECEPTORES NICOTINICOS NEURONALES (NRR) SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, DEMENCIA PRESENIL, INFLAMACION, SINDROME METABOLICO
PE2009001282A 2008-12-01 2009-11-30 Compuesto mono-l-malato (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y composiciones que lo contienen PE20100467A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11888508P 2008-12-01 2008-12-01

Publications (1)

Publication Number Publication Date
PE20100467A1 true PE20100467A1 (es) 2010-08-03

Family

ID=41549744

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001282A PE20100467A1 (es) 2008-12-01 2009-11-30 Compuesto mono-l-malato (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y composiciones que lo contienen

Country Status (27)

Country Link
US (3) US8153821B2 (es)
EP (3) EP2358705A1 (es)
JP (2) JP5698673B2 (es)
KR (2) KR20110094318A (es)
CN (2) CN102232072B (es)
AR (1) AR074239A1 (es)
AU (2) AU2009322630A1 (es)
BR (2) BRPI0922152A2 (es)
CA (2) CA2744191A1 (es)
CL (2) CL2009002146A1 (es)
CO (1) CO6382158A2 (es)
EA (1) EA021054B1 (es)
EC (1) ECSP11011135A (es)
ES (1) ES2403022T3 (es)
IL (2) IL212796A0 (es)
MX (2) MX2011005713A (es)
MY (1) MY159040A (es)
NZ (1) NZ593058A (es)
PE (1) PE20100467A1 (es)
RU (1) RU2507197C2 (es)
SA (1) SA109300715B1 (es)
SG (2) SG171432A1 (es)
TW (1) TW201024283A (es)
UA (1) UA106217C2 (es)
UY (1) UY32278A (es)
WO (2) WO2010065447A2 (es)
ZA (1) ZA201103497B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
PL3279195T3 (pl) * 2008-12-01 2020-12-14 Oyster Point Pharma, Inc. Synteza i nowe postacie soli (R)-5-((E)-2-pirolidyn-3-ylowinylo)pirymidyny
WO2013116371A1 (en) * 2012-01-30 2013-08-08 Roar Biomedical Inc. Ex vivo plasma enzyme activity assay using inhibitors as a negative control
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20160262372A1 (en) * 2015-03-13 2016-09-15 Cornell Kunz Extermination Treatment Appliance And Method
NZ746468A (en) 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
JP3745433B2 (ja) * 1995-02-02 2006-02-15 第一製薬株式会社 複素環式化合物
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
CZ83499A3 (cs) * 1996-09-13 1999-07-14 Schering Corporation Tricyklické sloučeniny, farmaceutický prostředek je obsahující a jejich použití
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
JPH1171345A (ja) * 1997-08-30 1999-03-16 Nippon Nohyaku Co Ltd 光学活性なピロリジン誘導体及びその中間体並びにそれらの製造法
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
AU2001271027B2 (en) * 2000-07-11 2005-07-07 Msd K.K. Ester derivatives
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
WO2007054777A1 (en) * 2005-11-09 2007-05-18 Orchid Chemicals & Pharmaceuticals Limited Depletion of isomer in cephalosporin antibiotic
WO2007134298A2 (en) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer

Also Published As

Publication number Publication date
US20140107163A1 (en) 2014-04-17
AR074239A1 (es) 2010-12-29
CN102227406B (zh) 2013-07-31
EA021054B1 (ru) 2015-03-31
AU2009322628A1 (en) 2010-06-10
IL212796A0 (en) 2011-07-31
US20110269975A1 (en) 2011-11-03
JP5615836B2 (ja) 2014-10-29
JP2012510473A (ja) 2012-05-10
IL212799A0 (en) 2011-07-31
EP2358670B1 (en) 2012-10-24
ZA201103497B (en) 2012-01-25
EP2358670A2 (en) 2011-08-24
TW201024283A (en) 2010-07-01
CA2744197A1 (en) 2010-06-10
EP2896619A1 (en) 2015-07-22
US8153821B2 (en) 2012-04-10
US8633227B2 (en) 2014-01-21
SG171876A1 (en) 2011-07-28
IL212799A (en) 2013-12-31
EP2358705A1 (en) 2011-08-24
CN102232072A (zh) 2011-11-02
WO2010065449A1 (en) 2010-06-10
SG171432A1 (en) 2011-07-28
MX2011005713A (es) 2011-06-17
KR20110094318A (ko) 2011-08-23
BRPI0922152A2 (pt) 2015-08-18
SA109300715B1 (ar) 2014-06-25
JP2012510472A (ja) 2012-05-10
RU2011127004A (ru) 2013-01-10
JP5698673B2 (ja) 2015-04-08
ES2403022T3 (es) 2013-05-13
CN102232072B (zh) 2014-09-24
RU2507197C2 (ru) 2014-02-20
EA201170736A1 (ru) 2011-12-30
NZ593058A (en) 2013-06-28
WO2010065447A3 (en) 2010-07-22
UY32278A (es) 2011-06-30
HK1157778A1 (en) 2012-07-06
BRPI0922630A2 (pt) 2016-01-05
CN102227406A (zh) 2011-10-26
ECSP11011135A (es) 2011-07-29
KR20110094100A (ko) 2011-08-19
CO6382158A2 (es) 2012-02-15
WO2010065447A2 (en) 2010-06-10
CL2009002146A1 (es) 2010-04-30
CA2744191A1 (en) 2010-06-10
US20120015983A1 (en) 2012-01-19
MY159040A (en) 2016-12-15
CL2009002145A1 (es) 2010-04-30
MX2011005712A (es) 2011-06-17
UA106217C2 (en) 2014-08-11
AU2009322630A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CO6290631A2 (es) Composición oral que contiene amino ácidos y un agente blanqueador
CL2009000404A1 (es) Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras.
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
CL2008000836A1 (es) Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CL2011002781A1 (es) Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer.
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
EA201100969A1 (ru) Солевые формы органического соединения
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
PE20100467A1 (es) Compuesto mono-l-malato (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y composiciones que lo contienen
CL2007001205A1 (es) Compuestos derivados de n-fenil-3-tio-4-fenil-azetedin-2-ona; procedimiento de preparacion; composicion farmaceutica; combinacion; uso en el tratamiento de una condicion hiperlipidemica, ateroesclerosis, alzheimer y tumores asociados a colesterol
CR11418A (es) Trans-clomifeno para el sindrome metabolico
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
MA37886A1 (fr) Nouvelles pyridinones bicycliques
BRPI0607379B8 (pt) composição farmacêutica de efeito analgésico
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed